US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
EN

ENOVStock

New York Stock Exchange · Healthcare · US

$17.69 last close 2026-10-09
Open in terminalCompare
Alert

Verdicts genuinely change. Free email alert the moment ENOV's does — no target price to set, unlike "Alert" above.

Sharia status
NOT COMPLIANT
Per In-house ratio engine
0 of 7 pass our own screen — all 7 agree here
Purification 100.00% *HTR non-permissible income 0.04%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure2 of 5 timeframes bullish · 73.9% aligned
VWAPPrice below VWAP ($17.86)
VolumeRelative volume 2.6× the 20-day average
Momentum10-day rate of change -4.2%

ENOV is currently considered not halal (non-compliant), per In-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

449 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →

Market & analysts
Wall Street consensus
BUY
19 analysts
Price target
$37.58
+112.5% · 12 analysts
Institutional own.
124.4% *
of shares
Momentum (10d)
-4.2%
rate of change
SMC grade
D · 37
73.9% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
0.04%
Non-permissible income — HTR, from filings (2026-07-03)
D · 37
SMC grade — 73.9% timeframe alignment
-4.2%
Rate of change (10d)
BUY
Wall Street consensus (19)
$37.58
Price target (+112.5%) · 12 analysts
124.4%
Institutional ownership *

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-07-03. ENOV files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail

RatioValueThresholdResult
Interest-bearing debt 122.38% 30.00% Fail
Interest-bearing investments 1.17% 30.00% Pass
Non-permissible income 0.04% 5.00% Pass

Usmani Fail

RatioValueThresholdResult
Interest-bearing debt 34.78% 33.00% Fail
Interest-bearing investments 0.33% 33.00% Pass
Non-liquid assets 87.93% at least 20.00% Pass
Non-permissible income 0.04% 5.00% Pass

MSCI Fail

RatioValueThresholdResult
Interest-bearing debt 34.78% 33.33% Fail
Cash + interest-bearing securities 0.33% 33.33% Pass
Accounts receivable 12.07% 33.33% Pass
Non-permissible income 0.04% 5.00% Pass

FTSE Fail

RatioValueThresholdResult
Interest-bearing debt 34.11% 33.33% Fail
Cash + interest-bearing securities 0.33% 33.33% Pass
Accounts receivable 12.07% 50.00% Pass
Non-permissible income 0.04% 5.00% Pass

Dow Jones Islamic Market Fail

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 71.24% 33.00% Fail
Cash + interest-bearing securities 0.68% 33.00% Pass
Accounts receivable 24.03% 33.00% Pass
Non-permissible income 0.04% 5.00% Pass

S&P Shariah Fail

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 59.23% 33.00% Fail
Cash + interest-bearing securities 0.57% 49.00% Pass
Accounts receivable 19.98% 49.00% Pass
Non-permissible income 0.04% 5.00% Pass

MSCI M-Series Fail

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 59.23% 33.33% Fail
Cash + interest-bearing securities 0.57% 33.33% Pass
Accounts receivable 20.55% 49.00% Pass
Non-permissible income 0.04% 5.00% Pass

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

AAOIFI Standard 21 (% of market cap)non permissible income ratio 5.0pts
Usmani (% of total assets)non permissible income ratio 5.0pts
Dow Jones Islamic Market (% of 24-mo avg market cap)non permissible income ratio 5.0pts
AAOIFI Standard 21 (% of market cap)debt ratio 92.4pts
Dow Jones Islamic Market (% of 24-mo avg market cap)debt ratio 38.2pts
S&P Shariah Indices (% of 36-mo avg market cap)debt ratio 26.2pts

The numbers the ratios are built from

Read from ENOV's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $2.2B 2026-07-03 RevenueFromContractWithCustomerExcludingAssessedTax
Interest-bearing debtShort and long-term borrowings $1.3B 2026-07-03 LongTermDebtNoncurrent, LongTermDebtCurrent
Cash and interest-bearing securitiesCash, equivalents and marketable securities $12.6M 2026-07-03 CashAndCashEquivalentsAtCarryingValue
Total assetsBalance sheet total $3.8B 2026-07-03 Assets
Market capDenominator for AAOIFI $1.1B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $2.2B 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $1.8B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $900.0K 2026-07-03 10-K text (no XBRL tag available)

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

What changed, and when

Verdict history for ENOV. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for ENOV has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

Tracked investors holding ENOV
InvestorFirmPositionWeightAs of
Ray Dalio Bridgewater Associates $2M 0.0% 2026-06-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

32.8729.0125.1521.2917.432025-10-132026-04-142026-10-09

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
15.95
S2
16.32
S1
16.88
PIVOT
17.25
R1
17.81
R2
18.18
R3
18.74

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
15.60 – 21.24
±15.31% from 18.42, made 2026-09-25 · resolves 2026-10-02
STRONG SELL
from 19 indicators
61.9% of our last 5789 forecasts landed inside their stated range, and 49.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsNEUTRAL
2 buy · 3 neutral · 2 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)38.40NEUTRAL
Stochastic %K (14)42.86NEUTRAL
CCI (20)-135.58BUY
Williams %R (14)-57.14NEUTRAL
MACD (12,26,9)0.19BUY
ROC (10)-4.17SELL
Momentum (10)-0.77SELL
EMA (10)17.98SELL
SMA (10)18.03SELL
EMA (20)18.60SELL
SMA (20)18.12SELL
EMA (30)19.41SELL
SMA (30)18.91SELL
EMA (50)20.71SELL
SMA (50)21.94SELL
EMA (100)22.35SELL
SMA (100)23.03SELL
EMA (200)23.91SELL
SMA (200)23.57SELL

About ENOV

Healthcare · Medical Devices

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.

enovis.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 41
⏰ 4H BEARISH 35
🕐 1H BULLISH 98
⏱ 15-Min BULLISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-4.2%
Rate of change (10d)
2.6×
Volume vs its 20-day average
-1.28
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

CLUSTER BUY   4 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-10-06 · Asset managers net 906615 (+2612)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.